Novel Blood Clot Rx Shows Potential
Antiplatelet medications, while highly effective, can put surgical patients at risk of serious bleeding. But a new, safer drug may be on the horizon.
A New Treatment Option for Adult Leukemia
Patients may now have an alternative to chemotherapy as their first line of defense against chronic lymphocytic leukemia (CLL).
New Rx Treats Most Common Inherited Bleeding Disorder
Patients with von Willebrand disease (VWD) lack a protein that's essential for healthy blood clotting. But a newly approved medication could help with that.
FDA Approves New von Willebrand Rx
The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD).
An Antibiotic Benefit for Childhood Leukemia
For kids with acute lymphoblastic leukemia (ALL), bacterial infections can cause dangerous complications. But a new treatment option may be able to help.
Bendeka Gets the Green Light
JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine.
A Big Month for Multiple Myeloma
Before November, there were seven FDA-approved medications to treat multiple myeloma. Now that November is over, there are 10.
A New Multiple Myeloma Treatment
Another treatment for multiple myeloma just got an OK from the FDA.
FDA Approves New Multiple Myeloma Rx
Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.
New Indication for Pradaxa
RIDGEFIELD, Conn., November 23, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Pradaxa® (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip replacement surgery.